Dimensional Fund Advisors LP Has $266,000 Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE)

Dimensional Fund Advisors LP cut its holdings in Cue Biopharma, Inc. (NASDAQ:CUE) by 50.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 214,089 shares of the company’s stock after selling 217,219 shares during the period. Dimensional Fund Advisors LP owned 0.44% of Cue Biopharma worth $266,000 as of its most recent filing with the SEC.

Separately, Vanguard Group Inc. boosted its holdings in shares of Cue Biopharma by 7.1% in the 1st quarter. Vanguard Group Inc. now owns 2,283,362 shares of the company’s stock worth $4,316,000 after acquiring an additional 150,457 shares in the last quarter. 35.04% of the stock is currently owned by institutional investors.

Cue Biopharma Trading Down 1.6 %

Shares of CUE stock opened at $1.21 on Tuesday. The firm has a 50 day moving average price of $0.74 and a two-hundred day moving average price of $1.18. The company has a quick ratio of 2.06, a current ratio of 2.06 and a debt-to-equity ratio of 0.11. The company has a market capitalization of $58.86 million, a PE ratio of -1.14 and a beta of 1.96. Cue Biopharma, Inc. has a 12-month low of $0.45 and a 12-month high of $3.25.

Cue Biopharma (NASDAQ:CUE) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.09. The business had revenue of $2.66 million for the quarter, compared to analysts’ expectations of $1.12 million. Cue Biopharma had a negative net margin of 566.02% and a negative return on equity of 142.93%. During the same period last year, the firm posted ($0.29) earnings per share. As a group, analysts predict that Cue Biopharma, Inc. will post -0.85 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts have issued reports on CUE shares. Stifel Nicolaus reduced their price objective on Cue Biopharma from $8.00 to $4.00 and set a “buy” rating on the stock in a report on Tuesday, August 20th. Piper Sandler lowered their price objective on shares of Cue Biopharma from $8.00 to $3.00 and set an “overweight” rating for the company in a research report on Friday, July 26th. Finally, JMP Securities lowered their price objective on shares of Cue Biopharma from $15.00 to $2.00 and set a “market outperform” rating for the company in a research report on Friday, July 26th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $5.00.

Cue Biopharma Company Profile

Cue Biopharma, Inc, a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer.